IF 6.8 2区医学

Rhinology Pub Date : 2025-07-29 DOI: 10.4193/Rhin24.204

P W Hellings, D Bertossi, C Cingi, S Claeys, J Constantinidis, D M Conti, A D'Souza, F Declau, H Foda, W Fokkens, P Gevaert, W Gubisch, S Halewyck, P Lekakis, G Liva, A Mesbahi, C Mcintosh, G Nolst Trenité, V Picavet, E Prokopakis, E Robotti, S Vandenbroeck, A Van Hoolst, T Vansweevelt, W Wagner

{"title":"Rhino(septo)plasty Informed Consent. Consensus by the European Rhinoplasty Course Faculty-EUFOREA.","authors":"P W Hellings, D Bertossi, C Cingi, S Claeys, J Constantinidis, D M Conti, A D'Souza, F Declau, H Foda, W Fokkens, P Gevaert, W Gubisch, S Halewyck, P Lekakis, G Liva, A Mesbahi, C Mcintosh, G Nolst Trenité, V Picavet, E Prokopakis, E Robotti, S Vandenbroeck, A Van Hoolst, T Vansweevelt, W Wagner","doi":"10.4193/Rhin24.204","DOIUrl":"https://doi.org/10.4193/Rhin24.204","url":null,"abstract":"Background: Patients seeking rhino(septo)plasty need to be adequately informed by their surgeon or surgical team members about the procedure, the expected outcomes, complication risks and post-operative care, and the available alternatives. A consensus on the content of an informed consent in rhino(septo)plasty is currently lacking despite the high unmet need.Methodology: The extended international faculty of the European Rhinoplasty Course in Brussels organized by EUFOREA has generated an overview of the current literature on rhinoplasty outcomes and complication rates, and available informed consents. A proposal for informed consent was elaborated, consensus reached and checked for legal validity.Results: An overview of reported outcomes and complication rates of rhino(septo)plasty are provided. Additionally, contents of existing consent forms for rhino(septo)plasty surgery are compared with requirements found in literature on informed consent, leading to a proposal of informed consent including relevant information according to expert consensus.Conclusions: An informed consent form for rhino(septo)plasty is proposed by the international faculty of the European Rhinoplasty Course, that might serve rhinoplasty surgeons in the development of their informd consent documents.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733018","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Combined European and Japanese criteria to diagnose eosinophilic chronic rhinosinusitis. 结合欧洲和日本标准诊断嗜酸性慢性鼻窦炎。

IF 6.8 2区医学

Rhinology Pub Date : 2025-07-29 DOI: 10.4193/Rhin25.048

T Kumai, M Kono, R Sato, T Terazawa, R Hayashi, T Inoue, R Wakisaka, H Komatsuda, H Yamaki, K Ohara, T Nagato, K Kishibe, Y Takewa, M Takahara

引用次数: 0

Negative pressure drainage vs. nasal packing after septoplasty: a randomized clinical trial. 中隔成形术后负压引流与鼻填塞：一项随机临床试验。

IF 6.8 2区医学

Rhinology Pub Date : 2025-07-29 DOI: 10.4193/Rhin25.112

Y Tu, T Jiang, G Zhao, L Xiao, L Shi, F Zhong, A Chen

{"title":"Negative pressure drainage vs. nasal packing after septoplasty: a randomized clinical trial.","authors":"Y Tu, T Jiang, G Zhao, L Xiao, L Shi, F Zhong, A Chen","doi":"10.4193/Rhin25.112","DOIUrl":"https://doi.org/10.4193/Rhin25.112","url":null,"abstract":"Background: Negative pressure drainage is a commonly used method in surgery, but studies applying negative pressure drainage in septoplasty are relatively few.Methodology: A randomized clinical trial was conducted to compare negative pressure drainage and nasal packing after septoplasty. Patients with nasal septal deviation underwent septoplasty from November 2023 to March 2024 were enrolled. Symptom scores and quality of life scores were assessed on postoperative day 1, day 5, and at 1 month to evaluate postoperative comfort.Results: A total of 95 patients completed the study, the median (IQR) age was 29 (21, 43) years, and 73 (77%) identified as male. 48 (51%) patients were randomized to nasal packing group and 47 (49%) to negative pressure group. On postoperative day 1, the negative pressure group showed significantly lower symptom scores for nasal congestion, rhinorrhea, olfactory dysfunction, headache, eye discomfort, ear fullness, and better quality of life compared to the packing group. On postoperative day 5, the negative pressure group showed significantly lower scores for olfactory dysfunction and ear fullness compared to the packing group. There was no significant difference in effective rate and postoperative complications rate between negative pressure group and packing group. The cost-effectiveness ratio for the negative pressure group was significantly lower than the packing group.Conclusions: Negative pressure drainage after septoplasty significantly improves postoperative comfort in the first days after surgery, without affecting surgical efficacy or safety, and helps reduce medical costs.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144744571","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The use of fascia lata can minimize olfactory damage in endoscopic endonasal skull base surgery. 在鼻内窥镜颅底手术中，阔筋膜的使用可以减少嗅觉损伤。

IF 6.8 2区医学

Rhinology Pub Date : 2025-07-29 DOI: 10.4193/Rhin24.522

Y Wu, Y Xue, M Zheng, H Wu, Y Zhang, Q Cai, T Zhao

{"title":"The use of fascia lata can minimize olfactory damage in endoscopic endonasal skull base surgery.","authors":"Y Wu, Y Xue, M Zheng, H Wu, Y Zhang, Q Cai, T Zhao","doi":"10.4193/Rhin24.522","DOIUrl":"https://doi.org/10.4193/Rhin24.522","url":null,"abstract":"Objective: The purpose of this study was to compare the impact of using fascia lata versus a nasoseptal flap for skull base repair on olfactory function following endoscopic endonasal skull base surgery.Methods: Patients who underwent the endoscopic endonasal transsphenoidal approach (EETA) or the extended endoscopic endonasal transsphenoidal approach (EEETA) were included in this study. The study included 80 patients who underwent skull base defect repair using fascia lata, while the control group consisted of 160 patients who underwent skull base defect repair using a nasoseptal flap. Preoperative demographic data, skull base repair techniques, postoperative sinonasal symptoms and the incidence of cerebrospinal fluid (CSF) leakage were compared between the two groups.Results: Olfactory dysfunction was significantly worse at 3, 6 and12 months after surgery than before surgery in the nasoseptal flap repair group, although olfactory function partially recovered at 12 months after surgery. Additionally, we found that non-validated visual analogue scale (VAS, 0-100 mm) and validated cross-cultural smell identification test (CC-SIT) and the butanol threshold test (BTT) olfactory impairment at 12 months after surgery were significantly worse in the nasoseptal flap repair group than in the fascia lata repair group. Furthermore, no significant difference in the incidence of CSF leakage was noted between the two groups.Conclusions: For endoscopic endonasal surgery, the use of a nasoseptal flap for skull base repair can cause severe olfactory impairment. The use of fascia lata for skull base repair can be considered an alternative method to minimize damage to olfactory function.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":6.8,"publicationDate":"2025-07-29","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144733019","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Effect of calcifediol on chronic rhinosinusitis, a randomized clinical trial. 钙化二醇治疗慢性鼻窦炎的随机临床试验。

IF 4.8 2区医学

Rhinology Pub Date : 2025-07-27 DOI: 10.4193/Rhin25.070

M Popko-Zagor, P Jandziak, J Sierdziński, N Rusetska, E Sarnowska

{"title":"Effect of calcifediol on chronic rhinosinusitis, a randomized clinical trial.","authors":"M Popko-Zagor, P Jandziak, J Sierdziński, N Rusetska, E Sarnowska","doi":"10.4193/Rhin25.070","DOIUrl":"https://doi.org/10.4193/Rhin25.070","url":null,"abstract":"Background: Recent studies suggest that intranasally administered vitamin D can be an effective treatment for patients with chronic rhinosinusitis (CRS). We performed a double-blind, placebo-controlled, randomized clinical trial to evaluate the effect of adding calcifediol to saline sinus irrigation with budesonide for patients with CRS.Methods: A total of 113 adult patients with CRS were enrolled. Patients were randomized to either calcifediol (n = 58, 51%) or placebo (n = 55, 49%) lavage and were instructed to irrigate both nasal cavities twice daily for 21 days, with either calcifediol or placebo dissolved in a solution of saline with budesonide. The primary outcome measure was the change in Sino-Nasal Outcome Test (SNOT-22) scores, endoscopic examination scored by the Lund-Kennedy (L-K) grading system, and physician-reported response to treatment, as measured with decreased need for nasal steroids/cessation of nasal steroids in the calcifediol group compared with the placebo group. The secondary outcome measures included the change in serum 25(OH)D concentration and the correlation of results with other clinical data.Results: 108 patients completed the trial. Significant changes in SNOT-22 score, L-K score and serum 25(OH)D were reported between the 2 study groups. A significant percentage of participants in the calcifediol group could cease nasal steroids.Conclusion: Calcifediol in saline nasal lavage with budesonide results in clinically significant benefits beyond the benefits of saline with budesonide alone for patients with CRS.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-27","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144718281","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

The changing paradigm for cystic fibrosis in rhinology. 鼻内科囊性纤维化的改变范例。

IF 4.8 2区医学

Rhinology Pub Date : 2025-07-22 DOI: 10.4193/Rhin25.904

A R Sedaghat

引用次数: 0

Establishing validity of a novel patient-centered and directly measurable definition of acute exacerbation of chronic rhinosinusitis. 建立一种新的以患者为中心的、可直接测量的慢性鼻窦炎急性加重定义的有效性。

IF 4.8 2区医学

Rhinology Pub Date : 2025-07-17 DOI: 10.4193/Rhin24.378

F A Houssein, A R Sedaghat, K M Phillips

{"title":"Establishing validity of a novel patient-centered and directly measurable definition of acute exacerbation of chronic rhinosinusitis.","authors":"F A Houssein, A R Sedaghat, K M Phillips","doi":"10.4193/Rhin24.378","DOIUrl":"https://doi.org/10.4193/Rhin24.378","url":null,"abstract":"BACKGROUND A patient-centered and directly measurable definition for acute exacerbation of chronic rhinosinusitis (AECRS) has been developed as \"a flare up of symptoms beyond day-to-day variation, lasting at least 3 days, and to which a distinct negative impact on a patient's quality of life (QOL) or functionality can be attributed\". Our aim is to understand how this definition correlates with previously used metrics.Methodology: Cross-sectional study of chronic rhinosinusitis (CRS) patients. The number of AECRS (using this novel definition), courses of CRS-related systemic antibiotics and corticosteroids taken for these AECRS, and number of asthma exacerbations in the past 6 months was queried. Disease-specific quality of life was measured using the 22-item Sinonasal Outcome Test.Results: A total of 237 CRS patients were enrolled. In the 6-month period prior to study enrollment, the mean number of AECRS was 4.2 while the mean number of systemic antibiotics or corticosteroids taken for these AECRS was 1.6 reflecting patients received rescue medication for 33% of AECRS. The number of AECRS was weakly correlated with number of systemic rescue medications and SNOT-22 score. For asthmatic CRS patients, numbers of AECRS and asthma exacerbations were correlated. Finally, comorbidities were associated with higher AECRS frequency by 29% in migraine and 41% in active tobacco users.Conclusions: We achieved our aim by showing the AECRS definition correlates with systemic rescue medication usage, disease-specific QOL and asthma exacerbations. Our results demonstrate that indirect measures of AECRS may not capture all AECRS. Furthermore, comorbid migraine and tobacco use are associated with AECRS frequency.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-17","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144660083","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Antimicrobial activity of simvastatin against chronic rhinosinusitis-related Staphylococcus aureus: an in vitro study. 辛伐他汀对慢性鼻窦炎相关金黄色葡萄球菌的抗菌活性：一项体外研究

IF 4.8 2区医学

Rhinology Pub Date : 2025-07-14 DOI: 10.4193/Rhin25.023

S P Goldie, L P Lau, H A S Jones, P G Harries, A F Walls, R J Salib

{"title":"Antimicrobial activity of simvastatin against chronic rhinosinusitis-related Staphylococcus aureus: an in vitro study.","authors":"S P Goldie, L P Lau, H A S Jones, P G Harries, A F Walls, R J Salib","doi":"10.4193/Rhin25.023","DOIUrl":"https://doi.org/10.4193/Rhin25.023","url":null,"abstract":"Introduction: Staphylococcus aureus (S. aureus) in chronic rhinosinusitis (CRS), particularly when localised intracellularly, is linked to disease recalcitrance and poor post-surgical outcomes. Antibiotics frequently fail to penetrate the mammalian cell membrane, resulting in an inability to address the intracellular component of S. aureus. This contributes to treatment failure and development of antimicrobial resistance. We investigated the antimicrobial effects of simvastatin, a widely used, inexpensive medication with extracellular and intracellular antimicrobial properties, against CRS-related S. aureus.Methods: Simvastatin's antimicrobial activity, in prodrug and hydroxy acid forms, was assessed against S. aureus using the broth dilution method to determine the minimal inhibitory concentration (MIC). Intracellular activity of simvastatin was evaluated by pre-treating S. aureus-infected LAD2 mast cells with simvastatin and performing colony forming unit (CFU) enumeration and confocal microscopy. Cell viability was assessed using lactate dehydrogenase (LDH) assays.Results: Simvastatin exhibited an extracellular MIC of 40 mmol/l against S. aureus. Intracellularly, it significantly reduced the bacterial burden by 46-fold in a dose-dependent manner between concentrations of 0.1-100 mmol/l. Toxicity to LAD2 cells was observed at 100 mmol/l. Confocal microscopy revealed a lower percentage of infected cells in the group pretreated with 30 μmol/l simvastatin (15.3%) compared to untreated cells (32.8%). Simvastatin hydroxy acid demonstrated no antimicrobial activity against S. aureus.Conclusions: Simvastatin demonstrates in vitro antimicrobial activity against CRS-related S. aureus with the potential for repurposing as a novel antibiotic-sparing topical agent for the treatment of refractory CRS. This could improve surgical outcomes andreduce the risk of antimicrobial resistance.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144627002","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

Olfactory implants: international opinion paper on emerging technologies and clinical applications. 嗅觉植入物：关于新兴技术和临床应用的国际意见文件。

IF 4.8 2区医学

Rhinology Pub Date : 2025-07-14 DOI: 10.4193/Rhin24.523

K L Whitcroft, A K Hernandez, P Andrews, A Altundag, H Benkhatar, M Bensafi, C Boëx, F Calegari, D H Coelho, R M Costanzo, V Druet, W Esposito, A Perez Fornos, S Gane, C A Hintschich, E H Holbrook, J Hsieh, C Huart, M Kobayashi, I Konstantinidis, S P Lacour, B N Landis, C S S Lipp, A Macchi, C Mignot, E Mori, T Myuran, H Nishijima, Z M Patel, C Philpott, D Podlesek, W Polanski, R M Richardson, P Rombaux, P Senn, R Sipione, S Weise, T Hummel

{"title":"Olfactory implants: international opinion paper on emerging technologies and clinical applications.","authors":"K L Whitcroft, A K Hernandez, P Andrews, A Altundag, H Benkhatar, M Bensafi, C Boëx, F Calegari, D H Coelho, R M Costanzo, V Druet, W Esposito, A Perez Fornos, S Gane, C A Hintschich, E H Holbrook, J Hsieh, C Huart, M Kobayashi, I Konstantinidis, S P Lacour, B N Landis, C S S Lipp, A Macchi, C Mignot, E Mori, T Myuran, H Nishijima, Z M Patel, C Philpott, D Podlesek, W Polanski, R M Richardson, P Rombaux, P Senn, R Sipione, S Weise, T Hummel","doi":"10.4193/Rhin24.523","DOIUrl":"https://doi.org/10.4193/Rhin24.523","url":null,"abstract":"Olfactory dysfunction affects a large proportion of the general population and causes significant personal and societal burden. At present, there are limited treatment options available. Though as yet experimental and untested in people, olfactory implants are a novel form of neuroprosthesis, modelled on existing implants for other sensory deficits such as hearing loss. Advances in this field have been rapid, yet there have been no unified efforts to collate current knowledge or guide such advances towards maximum patient benefit. In this Opinion Paper, leaders in the field have come together to provide an overview of current and emerging knowledge and technology relating to olfactory implants. In an effort to guide innovation towards maximum patient benefit, we also provide expert agreed statements on theoretical clinical aspects of olfactory implantation, including patient selection, implantation sites and potential complications, as well as post-implantation support requirements. Technical aspects will be discussed, with a clinical, device orientated focus. Finally, the ethics of olfactory implantation will be considered. We hope this document will serve as a useful roadmap to guide future clinical and basic research in the field.","PeriodicalId":21361,"journal":{"name":"Rhinology","volume":" ","pages":""},"PeriodicalIF":4.8,"publicationDate":"2025-07-14","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":null,"resultStr":null,"platform":"Semanticscholar","paperid":"144637901","PeriodicalName":null,"FirstCategoryId":null,"ListUrlMain":null,"RegionNum":2,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":"","EPubDate":null,"PubModel":null,"JCR":null,"JCRName":null,"Score":null,"Total":0}

引用次数: 0

De-escalation of dupilumab for chronic rhinosinusitis with nasal polyps: analysis of outcomes after modified dosing regimen. 降低dupilumab治疗慢性鼻窦炎伴鼻息肉：改进给药方案后的结果分析

IF 4.8 2区医学

Rhinology Pub Date : 2025-07-14 DOI: 10.4193/Rhin25.151

L D'Ascanio, P Gradoni, L Pierucci, G Motta, N Y BuSaba, M J Brenner, A Di Stadio

引用次数: 0

Rhinology最新文献